SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dr. Reddy’s Laboratories Limited

NEW YORK--()--Levi & Korsinsky announces it has commenced an investigation of Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s” or the “Company”) (NYSE:RDY) concerning possible violations of federal securities laws.

On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. Then on August 10, 2017, Dr. Reddy’s disclosed that the Regierung von Oberbayern (the district government of Upper Bavaria) did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary Betapharm Arzneimittel, located in India. Following this news, shares of Dr. Reddy’s stock was down more than 5% on intraday trading on August 10, 2017. To obtain additional information, go to:

http://www.zlkdocs.com/RDY-Info-Request-Form-6031

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq., 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com

Release Summary

Levi & Korsinsky announces it has commenced an investigation of Dr. Reddy’s Laboratories Limited

Contacts

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq., 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com